“Diabetic Nephropathy Epidemiology” report has been added to DelveInsight
Overview of Diabetic Nephropathy Epidemiology, pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies
Request for free sample copy of this report- https://www.delveinsight.com/sample-request/diabetic-nephropathy-epidemiology-forecast
Important fact of the report
- As per some of the research studies, diabetic nephropathy develops in approximately 30% of patients with type 1 diabetes mellitus (DM1) and approximately 40% of patients with type 2 diabetes mellitus (DM2) which means that patients with Type 2 diabetes are at a higher risk of developing diabetic nephropathy
- Approximately 25% of individuals with diabetes have DKD, and is anticipated to increase by around 52-54% in the coming years, in the United States. In addition to this, Diabetes is responsible for around 30-40% of all end-stage renal disease (ESRD) cases in the United States.
- Diabetic nephropathy is one of the most significant long-term complications. A nation-wide survey in Japan showed that the most common primary cause of renal failure among new dialysis patients was diabetic nephropathy (43.8%)
Diabetic Nephropathy Treatment
The first step in treating diabetic nephropathy is to monitor and manage diabetes, as well as high blood pressure if necessary (hypertension). Kidney disease and other complications may be avoided or delayed with proper blood sugar and hypertension treatment. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can help to lower blood pressure, protect kidney function, and prevent further damage.
Diabetic Nephropathy Prevalent Population
The risk factors for diabetic nephropathy incorporate smoking, comorbidities and is more prevalent in people who are more than 62-65 years old. An individual with diabetic nephropathy may not experience any symptoms in the early stages. Changes in blood pressure and fluid equilibrium in the body, on the other hand, may already be present. Waste products can accumulate in the blood over time, causing symptoms. Swollen feet and ankles, darker urine, shortness of breath are some of the symptoms presented in the later stages.
Diabetic Nephropathy Epidemiology Segmentation
The Diabetic Nephropathy epidemiology covered in the report provides historical as well as forecasted Diabetic Nephropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030. The DelveInsight Diabetic Nephropathy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Diabetic Nephropathy: Report Highlights
- 11-Year Forecast of Diabetic Nephropathy epidemiology
- 7MM Coverage
- Total Cases of Diabetic Nephropathy
- Total Cases of Diabetic Nephropathy according to segmentation
- Diagnosed cases of Diabetic Nephropathy
Request for free sample copy of this report- https://www.delveinsight.com/sample-request/diabetic-nephropathy-epidemiology-forecast
Following is the table of content of Diabetic Nephropathy report
1. Key Insights
2. Executive Summary of Diabetic Nephropathy
3. Diabetic Nephropathy: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Diabetic Nephropathy: Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global Diabetic Nephropathy market
- Quantify patient populations in the global Diabetic Nephropathy market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Diabetic Nephropathy therapeutics in each of the markets covered
- Understand the magnitude of Diabetic Nephropathy population by its epidemiology
- The Diabetic Nephropathy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Related Reports
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/